Share Price and Basic Stock Data
Last Updated: October 22, 2025, 8:40 am
| PEG Ratio | -10.78 |
|---|
Analyst Insight & Comprehensive Analysis
Business Overview and Revenue Trends
Emmessar Biotech & Nutrition Ltd operates within the chemicals sector, specifically focusing on inorganic products. The company’s share price stands at ₹31.5, giving it a market capitalization of ₹15.8 Cr. Over the years, Emmessar has experienced significant fluctuations in revenue, with sales recorded at ₹0.36 Cr in March 2022, declining to ₹0.56 Cr in March 2024, and then slightly increasing to ₹0.61 Cr in March 2025. Quarterly trends depict erratic performance, with sales peaking at ₹0.43 Cr in December 2022 but subsequently dropping to ₹0.07 Cr in both June and September 2023. The company has also faced challenges with operational efficiency, as reflected in its operating profit margin (OPM) which has been negative for several quarters, notably reaching -400% in June 2023. Such volatility in revenue and operating performance highlights the company’s struggle to establish a stable revenue stream and maintain operational effectiveness.
Profitability and Efficiency Metrics
Profitability metrics for Emmessar Biotech indicate a challenging landscape. The company’s net profit was ₹0.32 Cr for the latest reporting period, reflecting a marginal increase from ₹0.50 Cr in March 2023. However, the operating profit margin has been consistently negative, with the latest figure at -300%. The interest coverage ratio is exceptionally high at 1760.67x, suggesting that the company has no interest obligations, thus allowing it to focus on operational improvements without the burden of debt. Return on equity (ROE) is reported at 4.23%, while return on capital employed (ROCE) is at 12.6%, both indicating lower profitability relative to the sector’s norms. Moreover, the cash conversion cycle stands at 242.49 days, indicating inefficiencies in managing working capital, which could impact liquidity and operational flexibility.
Balance Sheet Strength and Financial Ratios
Emmessar Biotech boasts a robust balance sheet with no borrowings, reflecting a debt-to-equity ratio of 0.00. This positions the company favorably in terms of financial stability, allowing it to avoid interest expenses and maintain liquidity. The reserves have increased from ₹1.67 Cr in March 2023 to ₹2.71 Cr in March 2025, demonstrating a strengthening position. The current ratio is an impressive 15.67, indicating exceptional short-term liquidity, while the quick ratio stands at 15.41, further confirming the company’s ability to meet its short-term liabilities. However, the price-to-book value ratio is 1.97x, which is relatively high compared to typical sector averages, suggesting that the stock may be overvalued based on its current asset base. These financial ratios collectively portray a company that is well-capitalized but faces challenges in operational profitability.
Shareholding Pattern and Investor Confidence
The shareholding pattern of Emmessar Biotech reveals a strong promoter presence, holding 59.53% of the equity, which indicates a significant level of control and commitment from the founding members. The public holds 40.28%, while domestic institutional investors (DIIs) hold a minimal stake of 0.19%. The number of shareholders has seen a slight increase, recording 7,173 shareholders as of the latest period. This stability in shareholder base, coupled with the high promoter holding, suggests a level of investor confidence in the company’s long-term potential. However, the absence of foreign institutional investment (FIIs) could indicate a lack of broader market interest, which may affect liquidity and overall market perception. The concentration of ownership among promoters also raises concerns regarding governance and decision-making processes, which could impact minority shareholder interests.
Outlook, Risks, and Final Insight
If margins sustain a positive trajectory and operational efficiencies improve, Emmessar Biotech could leverage its strong balance sheet to enhance shareholder value. The absence of debt allows for potential reinvestment in growth initiatives, which could stabilize revenue streams. However, risks remain, including the company’s ongoing struggle with negative operating margins and a prolonged cash conversion cycle that may hinder liquidity. Additionally, reliance on a concentrated promoter stake poses governance risks that could impact broader investor sentiment. Strengthening operational practices and addressing working capital inefficiencies will be critical for Emmessar to achieve improved profitability and attract institutional investment. Overall, the company must navigate these challenges while capitalizing on its financial strengths to create sustainable growth pathways in the competitive chemicals sector.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Emmessar Biotech & Nutrition Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Fischer Medical Ventures Ltd | 6,475 Cr. | 99.8 | 125/60.0 | 980 | 5.29 | 0.01 % | 1.08 % | 0.70 % | 1.00 |
| Emmessar Biotech & Nutrition Ltd | 15.4 Cr. | 30.9 | 64.0/25.8 | 38.6 | 15.4 | 0.00 % | 12.6 % | 4.23 % | 10.0 |
| Cochin Minerals & Rutile Ltd | 231 Cr. | 295 | 415/238 | 11.1 | 211 | 2.71 % | 23.3 % | 15.0 % | 10.0 |
| Archean Chemical Industries Ltd | 8,058 Cr. | 653 | 730/408 | 36.5 | 152 | 0.46 % | 16.0 % | 12.0 % | 2.00 |
| Alufluoride Ltd | 354 Cr. | 452 | 544/341 | 17.2 | 144 | 0.66 % | 23.6 % | 20.8 % | 10.0 |
| Industry Average | 5,588.50 Cr | 508.87 | 156.39 | 153.36 | 0.45% | 13.95% | 10.65% | 7.00 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 0.21 | 0.07 | 0.43 | 0.32 | 0.07 | 0.08 | 0.33 | 0.08 | 0.08 | 0.34 | 0.10 | 0.10 | 0.09 |
| Expenses | 0.36 | 0.27 | 0.60 | 0.48 | 0.35 | 0.30 | 0.54 | 0.47 | 0.36 | 0.42 | 0.38 | 0.43 | 0.36 |
| Operating Profit | -0.15 | -0.20 | -0.17 | -0.16 | -0.28 | -0.22 | -0.21 | -0.39 | -0.28 | -0.08 | -0.28 | -0.33 | -0.27 |
| OPM % | -71.43% | -285.71% | -39.53% | -50.00% | -400.00% | -275.00% | -63.64% | -487.50% | -350.00% | -23.53% | -280.00% | -330.00% | -300.00% |
| Other Income | 0.44 | 0.43 | 0.44 | 0.42 | 0.46 | 0.53 | 0.53 | 0.48 | 0.46 | 0.51 | 0.43 | 0.61 | 0.53 |
| Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 | 0.02 |
| Profit before tax | 0.27 | 0.21 | 0.25 | 0.24 | 0.16 | 0.29 | 0.30 | 0.07 | 0.16 | 0.41 | 0.13 | 0.26 | 0.24 |
| Tax % | 25.93% | 33.33% | 108.00% | 20.83% | 68.75% | 31.03% | 56.67% | -285.71% | 43.75% | 31.71% | 84.62% | 126.92% | 25.00% |
| Net Profit | 0.20 | 0.13 | -0.02 | 0.20 | 0.05 | 0.20 | 0.13 | 0.27 | 0.09 | 0.28 | 0.02 | -0.07 | 0.17 |
| EPS in Rs | 0.40 | 0.26 | -0.04 | 0.40 | 0.10 | 0.40 | 0.26 | 0.54 | 0.18 | 0.56 | 0.04 | -0.14 | 0.34 |
Last Updated: August 19, 2025, 3:48 pm
Below is a detailed analysis of the quarterly data for Emmessar Biotech & Nutrition Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 0.09 Cr.. The value appears to be declining and may need further review. It has decreased from 0.10 Cr. (Mar 2025) to 0.09 Cr., marking a decrease of 0.01 Cr..
- For Expenses, as of Jun 2025, the value is 0.36 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 0.43 Cr. (Mar 2025) to 0.36 Cr., marking a decrease of 0.07 Cr..
- For Operating Profit, as of Jun 2025, the value is -0.27 Cr.. The value appears strong and on an upward trend. It has increased from -0.33 Cr. (Mar 2025) to -0.27 Cr., marking an increase of 0.06 Cr..
- For OPM %, as of Jun 2025, the value is -300.00%. The value appears strong and on an upward trend. It has increased from -330.00% (Mar 2025) to -300.00%, marking an increase of 30.00%.
- For Other Income, as of Jun 2025, the value is 0.53 Cr.. The value appears to be declining and may need further review. It has decreased from 0.61 Cr. (Mar 2025) to 0.53 Cr., marking a decrease of 0.08 Cr..
- For Interest, as of Jun 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.00 Cr..
- For Depreciation, as of Jun 2025, the value is 0.02 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2025) which recorded 0.02 Cr..
- For Profit before tax, as of Jun 2025, the value is 0.24 Cr.. The value appears to be declining and may need further review. It has decreased from 0.26 Cr. (Mar 2025) to 0.24 Cr., marking a decrease of 0.02 Cr..
- For Tax %, as of Jun 2025, the value is 25.00%. The value appears to be improving (decreasing) as expected. It has decreased from 126.92% (Mar 2025) to 25.00%, marking a decrease of 101.92%.
- For Net Profit, as of Jun 2025, the value is 0.17 Cr.. The value appears strong and on an upward trend. It has increased from -0.07 Cr. (Mar 2025) to 0.17 Cr., marking an increase of 0.24 Cr..
- For EPS in Rs, as of Jun 2025, the value is 0.34. The value appears strong and on an upward trend. It has increased from -0.14 (Mar 2025) to 0.34, marking an increase of 0.48.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 3:25 am
| Metric | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1.37 | 2.19 | 1.98 | 2.61 | 1.27 | 0.63 | 3.40 | 6.99 | 0.36 | 1.02 | 0.56 | 0.61 | 0.63 |
| Expenses | 1.43 | 2.34 | 2.66 | 2.38 | 1.67 | 1.27 | 3.81 | 6.15 | 1.26 | 1.71 | 1.64 | 1.56 | 1.59 |
| Operating Profit | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.64 | -0.41 | 0.84 | -0.90 | -0.69 | -1.08 | -0.95 | -0.96 |
| OPM % | -4.38% | -6.85% | -34.34% | 8.81% | -31.50% | -101.59% | -12.06% | 12.02% | -250.00% | -67.65% | -192.86% | -155.74% | -152.38% |
| Other Income | 0.09 | 0.06 | 0.03 | 0.98 | 1.25 | 1.01 | 1.21 | 1.47 | 1.92 | 1.75 | 1.99 | 2.01 | 2.08 |
| Interest | 0.00 | 0.00 | 0.00 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Depreciation | 0.20 | 0.07 | 0.03 | 0.01 | 0.05 | 0.08 | 0.06 | 0.06 | 0.09 | 0.09 | 0.10 | 0.10 | 0.08 |
| Profit before tax | -0.17 | -0.16 | -0.68 | 1.19 | 0.80 | 0.29 | 0.74 | 2.25 | 0.93 | 0.97 | 0.81 | 0.96 | 1.04 |
| Tax % | 82.35% | -25.00% | -30.88% | 0.00% | -15.00% | -82.76% | -2.70% | 36.00% | 48.39% | 47.42% | 7.41% | 66.67% | |
| Net Profit | -0.31 | -0.12 | -0.47 | 1.19 | 0.91 | 0.53 | 0.75 | 1.45 | 0.48 | 0.50 | 0.75 | 0.32 | 0.40 |
| EPS in Rs | -0.62 | -0.24 | -0.94 | 2.38 | 1.82 | 1.06 | 1.50 | 2.90 | 0.96 | 1.00 | 1.50 | 0.64 | 0.80 |
| Dividend Payout % | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
YoY Net Profit Growth
| Year | 2014-2015 | 2015-2016 | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 61.29% | -291.67% | 353.19% | -23.53% | -41.76% | 41.51% | 93.33% | -66.90% | 4.17% | 50.00% | -57.33% |
| Change in YoY Net Profit Growth (%) | 0.00% | -352.96% | 644.86% | -376.72% | -18.23% | 83.27% | 51.82% | -160.23% | 71.06% | 45.83% | -107.33% |
Emmessar Biotech & Nutrition Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 11 years from 2014-2015 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | -12% |
| 5 Years: | -29% |
| 3 Years: | 19% |
| TTM: | 11% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 17% |
| 5 Years: | -20% |
| 3 Years: | -13% |
| TTM: | -42% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 10% |
| 5 Years: | 15% |
| 3 Years: | 2% |
| 1 Year: | -35% |
| Return on Equity | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 11% |
| 3 Years: | 7% |
| Last Year: | 4% |
Last Updated: September 5, 2025, 3:21 pm
Balance Sheet
Last Updated: July 25, 2025, 1:21 pm
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 | 5.00 |
| Reserves | -3.42 | -3.62 | -4.09 | -2.91 | -2.01 | -1.49 | -0.73 | 0.70 | 1.17 | 1.67 | 2.41 | 2.71 |
| Borrowings | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.07 | 0.00 | 0.00 | 0.00 | 0.08 | 0.11 | 0.00 |
| Other Liabilities | 0.65 | 1.03 | 1.36 | 1.13 | 0.92 | 1.59 | 1.86 | 2.11 | 1.04 | 1.19 | 1.23 | 1.51 |
| Total Liabilities | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 |
| Fixed Assets | 1.58 | 1.42 | 0.73 | 0.72 | 2.25 | 1.99 | 1.91 | 1.86 | 2.07 | 2.00 | 1.91 | 1.81 |
| CWIP | 0.00 | 0.00 | 0.00 | 0.80 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Investments | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 | 0.01 |
| Other Assets | 0.64 | 0.98 | 1.53 | 1.69 | 1.65 | 3.17 | 4.21 | 5.94 | 5.13 | 5.93 | 6.83 | 7.40 |
| Total Assets | 2.23 | 2.41 | 2.27 | 3.22 | 3.91 | 5.17 | 6.13 | 7.81 | 7.21 | 7.94 | 8.75 | 9.22 |
Below is a detailed analysis of the balance sheet data for Emmessar Biotech & Nutrition Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 5.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 5.00 Cr..
- For Reserves, as of Mar 2025, the value is 2.71 Cr.. The value appears strong and on an upward trend. It has increased from 2.41 Cr. (Mar 2024) to 2.71 Cr., marking an increase of 0.30 Cr..
- For Borrowings, as of Mar 2025, the value is 0.00 Cr.. The value appears to be improving (decreasing). Additionally, since Reserves exceed Borrowings, this is considered a positive sign. It has decreased from 0.11 Cr. (Mar 2024) to 0.00 Cr., marking a decrease of 0.11 Cr..
- For Other Liabilities, as of Mar 2025, the value is 1.51 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 1.23 Cr. (Mar 2024) to 1.51 Cr., marking an increase of 0.28 Cr..
- For Total Liabilities, as of Mar 2025, the value is 9.22 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 8.75 Cr. (Mar 2024) to 9.22 Cr., marking an increase of 0.47 Cr..
- For Fixed Assets, as of Mar 2025, the value is 1.81 Cr.. The value appears to be declining and may need further review. It has decreased from 1.91 Cr. (Mar 2024) to 1.81 Cr., marking a decrease of 0.10 Cr..
- For CWIP, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Investments, as of Mar 2025, the value is 0.01 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.01 Cr..
- For Other Assets, as of Mar 2025, the value is 7.40 Cr.. The value appears strong and on an upward trend. It has increased from 6.83 Cr. (Mar 2024) to 7.40 Cr., marking an increase of 0.57 Cr..
- For Total Assets, as of Mar 2025, the value is 9.22 Cr.. The value appears strong and on an upward trend. It has increased from 8.75 Cr. (Mar 2024) to 9.22 Cr., marking an increase of 0.47 Cr..
Notably, the Reserves (2.71 Cr.) exceed the Borrowings (0.00 Cr.), indicating a solid financial buffer.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
Free Cash Flow
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | -0.06 | -0.15 | -0.68 | 0.23 | -0.40 | -0.71 | -0.41 | 0.84 | -0.90 | -0.77 | -1.19 | -0.95 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 45.29 | 6.67 | 66.36 | 5.59 | 8.62 | 23.17 | 3.22 | 141.51 | 10.14 | 3.58 | 13.04 | 11.97 |
| Inventory Days | 267.67 | 335.80 | 136.88 | 121.67 | 52.14 | 2,049.62 | 272.56 | 7.24 | 196.54 | 127.75 | 164.25 | 230.53 |
| Days Payable | 121.67 | 150.87 | 76.04 | 76.04 | 5.79 | 1,628.46 | 189.61 | 51.70 | 56.15 | 0.00 | 18.25 | 0.00 |
| Cash Conversion Cycle | 191.29 | 191.60 | 127.20 | 51.22 | 54.97 | 444.33 | 86.18 | 97.05 | 150.52 | 131.33 | 159.04 | 242.49 |
| Working Capital Days | 29.31 | 38.33 | 22.12 | 85.31 | 175.31 | 457.70 | 30.06 | 79.37 | -60.83 | 114.51 | 91.25 | 35.90 |
| ROCE % | -9.60% | -10.81% | -39.30% | 80.00% | 31.50% | 17.66% | 25.48% | 45.14% | 15.67% | 15.02% | 11.35% | 12.61% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 0.61 | 1.48 | 0.99 | 0.94 | 2.88 |
| Diluted EPS (Rs.) | 0.61 | 1.48 | 0.99 | 0.94 | 2.88 |
| Cash EPS (Rs.) | 0.82 | 1.70 | 1.20 | 1.14 | 3.02 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 15.43 | 14.82 | 13.34 | 12.35 | 11.41 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 15.43 | 14.82 | 13.34 | 12.35 | 11.41 |
| Revenue From Operations / Share (Rs.) | 1.22 | 1.11 | 2.04 | 0.73 | 13.99 |
| PBDIT / Share (Rs.) | 2.11 | 1.82 | 2.12 | 2.05 | 4.63 |
| PBIT / Share (Rs.) | 1.92 | 1.63 | 1.94 | 1.86 | 4.51 |
| PBT / Share (Rs.) | 1.92 | 1.63 | 1.94 | 1.86 | 4.51 |
| Net Profit / Share (Rs.) | 0.63 | 1.50 | 1.01 | 0.95 | 2.90 |
| PBDIT Margin (%) | 172.95 | 163.94 | 104.05 | 280.54 | 33.07 |
| PBIT Margin (%) | 156.97 | 146.36 | 94.86 | 255.24 | 32.25 |
| PBT Margin (%) | 156.87 | 146.36 | 94.86 | 255.24 | 32.25 |
| Net Profit Margin (%) | 51.75 | 135.01 | 49.43 | 130.25 | 20.73 |
| Return on Networth / Equity (%) | 4.10 | 10.12 | 7.55 | 7.70 | 25.43 |
| Return on Capital Employeed (%) | 10.96 | 9.86 | 12.85 | 13.53 | 35.20 |
| Return On Assets (%) | 3.42 | 8.57 | 6.34 | 6.58 | 18.57 |
| Total Debt / Equity (X) | 0.00 | 0.01 | 0.01 | 0.00 | 0.00 |
| Asset Turnover Ratio (%) | 0.06 | 0.06 | 0.13 | 0.04 | 1.00 |
| Current Ratio (X) | 15.67 | 13.56 | 14.14 | 14.73 | 3.85 |
| Quick Ratio (X) | 15.41 | 13.38 | 13.82 | 14.52 | 3.80 |
| Inventory Turnover Ratio (X) | 0.64 | 0.56 | 0.67 | 0.24 | 4.14 |
| Interest Coverage Ratio (X) | 1760.67 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Coverage Ratio (Post Tax) (X) | 527.83 | 0.00 | 0.00 | 0.00 | 0.00 |
| Enterprise Value (Cr.) | 8.31 | 8.78 | 7.28 | 9.16 | 4.87 |
| EV / Net Operating Revenue (X) | 13.61 | 15.81 | 7.14 | 25.09 | 0.69 |
| EV / EBITDA (X) | 7.87 | 9.64 | 6.87 | 8.94 | 2.11 |
| MarketCap / Net Operating Revenue (X) | 24.86 | 26.74 | 12.16 | 37.65 | 1.05 |
| Price / BV (X) | 1.97 | 2.01 | 1.86 | 2.23 | 1.29 |
| Price / Net Operating Revenue (X) | 24.87 | 26.75 | 12.16 | 37.67 | 1.05 |
| EarningsYield | 0.02 | 0.05 | 0.04 | 0.03 | 0.19 |
After reviewing the key financial ratios for Emmessar Biotech & Nutrition Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 1.48 (Mar 24) to 0.61, marking a decrease of 0.87.
- For Diluted EPS (Rs.), as of Mar 25, the value is 0.61. This value is below the healthy minimum of 5. It has decreased from 1.48 (Mar 24) to 0.61, marking a decrease of 0.87.
- For Cash EPS (Rs.), as of Mar 25, the value is 0.82. This value is below the healthy minimum of 3. It has decreased from 1.70 (Mar 24) to 0.82, marking a decrease of 0.88.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.43. It has increased from 14.82 (Mar 24) to 15.43, marking an increase of 0.61.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 15.43. It has increased from 14.82 (Mar 24) to 15.43, marking an increase of 0.61.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 1.22. It has increased from 1.11 (Mar 24) to 1.22, marking an increase of 0.11.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 2.11. This value is within the healthy range. It has increased from 1.82 (Mar 24) to 2.11, marking an increase of 0.29.
- For PBIT / Share (Rs.), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.92, marking an increase of 0.29.
- For PBT / Share (Rs.), as of Mar 25, the value is 1.92. This value is within the healthy range. It has increased from 1.63 (Mar 24) to 1.92, marking an increase of 0.29.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 0.63. This value is below the healthy minimum of 2. It has decreased from 1.50 (Mar 24) to 0.63, marking a decrease of 0.87.
- For PBDIT Margin (%), as of Mar 25, the value is 172.95. This value is within the healthy range. It has increased from 163.94 (Mar 24) to 172.95, marking an increase of 9.01.
- For PBIT Margin (%), as of Mar 25, the value is 156.97. This value exceeds the healthy maximum of 20. It has increased from 146.36 (Mar 24) to 156.97, marking an increase of 10.61.
- For PBT Margin (%), as of Mar 25, the value is 156.87. This value is within the healthy range. It has increased from 146.36 (Mar 24) to 156.87, marking an increase of 10.51.
- For Net Profit Margin (%), as of Mar 25, the value is 51.75. This value exceeds the healthy maximum of 10. It has decreased from 135.01 (Mar 24) to 51.75, marking a decrease of 83.26.
- For Return on Networth / Equity (%), as of Mar 25, the value is 4.10. This value is below the healthy minimum of 15. It has decreased from 10.12 (Mar 24) to 4.10, marking a decrease of 6.02.
- For Return on Capital Employeed (%), as of Mar 25, the value is 10.96. This value is within the healthy range. It has increased from 9.86 (Mar 24) to 10.96, marking an increase of 1.10.
- For Return On Assets (%), as of Mar 25, the value is 3.42. This value is below the healthy minimum of 5. It has decreased from 8.57 (Mar 24) to 3.42, marking a decrease of 5.15.
- For Total Debt / Equity (X), as of Mar 25, the value is 0.00. This value is within the healthy range. It has decreased from 0.01 (Mar 24) to 0.00, marking a decrease of 0.01.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 0.06. There is no change compared to the previous period (Mar 24) which recorded 0.06.
- For Current Ratio (X), as of Mar 25, the value is 15.67. This value exceeds the healthy maximum of 3. It has increased from 13.56 (Mar 24) to 15.67, marking an increase of 2.11.
- For Quick Ratio (X), as of Mar 25, the value is 15.41. This value exceeds the healthy maximum of 2. It has increased from 13.38 (Mar 24) to 15.41, marking an increase of 2.03.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 0.64. This value is below the healthy minimum of 4. It has increased from 0.56 (Mar 24) to 0.64, marking an increase of 0.08.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 1,760.67. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 1,760.67, marking an increase of 1,760.67.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 527.83. This value is within the healthy range. It has increased from 0.00 (Mar 24) to 527.83, marking an increase of 527.83.
- For Enterprise Value (Cr.), as of Mar 25, the value is 8.31. It has decreased from 8.78 (Mar 24) to 8.31, marking a decrease of 0.47.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 13.61. This value exceeds the healthy maximum of 3. It has decreased from 15.81 (Mar 24) to 13.61, marking a decrease of 2.20.
- For EV / EBITDA (X), as of Mar 25, the value is 7.87. This value is within the healthy range. It has decreased from 9.64 (Mar 24) to 7.87, marking a decrease of 1.77.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 24.86. This value exceeds the healthy maximum of 3. It has decreased from 26.74 (Mar 24) to 24.86, marking a decrease of 1.88.
- For Price / BV (X), as of Mar 25, the value is 1.97. This value is within the healthy range. It has decreased from 2.01 (Mar 24) to 1.97, marking a decrease of 0.04.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 24.87. This value exceeds the healthy maximum of 3. It has decreased from 26.75 (Mar 24) to 24.87, marking a decrease of 1.88.
- For EarningsYield, as of Mar 25, the value is 0.02. This value is below the healthy minimum of 5. It has decreased from 0.05 (Mar 24) to 0.02, marking a decrease of 0.03.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Emmessar Biotech & Nutrition Ltd:
- Net Profit Margin: 51.75%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 10.96% (Industry Average ROCE: 13.95%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 4.1% (Industry Average ROE: 10.65%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 527.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 15.41
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 38.6 (Industry average Stock P/E: 156.39)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 0
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 51.75%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Chemicals - Inorganic - Others | Plot No.T-3/2, MIDC Area, Raigad District Maharashtra 410208 | enquiries@ebnl.org http://www.ebnl.org |
| Management | |
|---|---|
| Name | Position Held |
| Mr. Srinivasa Raghavan Mathurakavi Ayyangar | Managing Director |
| Dr.(Mrs.) Sarada S Raghavan | Non Executive Director |
| Mrs. Rajalakshmi Srinivasa Raghavan | Non Executive Director |
| Dr.(Mrs.) Anuradha S Raghavan | Non Executive Director |
| Mr. Jeyavel B Nadar | Whole Time Director |
| Mr. Anantharama S Subramanian | Ind. Non-Executive Director |
| Mr. Milind Sitaram Desai | Ind. Non-Executive Director |
| Mr. Veeraraghavan Ranganathan | Addnl.Non Exe.Independent Director |
| Mr. Dinesh Kumar Deora | Addnl.Non Exe.Independent Director |
FAQ
What is the intrinsic value of Emmessar Biotech & Nutrition Ltd?
Emmessar Biotech & Nutrition Ltd's intrinsic value (as of 24 October 2025) is 20.52 which is 33.59% lower the current market price of 30.90, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 15.4 Cr. market cap, FY2025-2026 high/low of 64.0/25.8, reserves of ₹2.71 Cr, and liabilities of 9.22 Cr.
What is the Market Cap of Emmessar Biotech & Nutrition Ltd?
The Market Cap of Emmessar Biotech & Nutrition Ltd is 15.4 Cr..
What is the current Stock Price of Emmessar Biotech & Nutrition Ltd as on 24 October 2025?
The current stock price of Emmessar Biotech & Nutrition Ltd as on 24 October 2025 is 30.9.
What is the High / Low of Emmessar Biotech & Nutrition Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Emmessar Biotech & Nutrition Ltd stocks is 64.0/25.8.
What is the Stock P/E of Emmessar Biotech & Nutrition Ltd?
The Stock P/E of Emmessar Biotech & Nutrition Ltd is 38.6.
What is the Book Value of Emmessar Biotech & Nutrition Ltd?
The Book Value of Emmessar Biotech & Nutrition Ltd is 15.4.
What is the Dividend Yield of Emmessar Biotech & Nutrition Ltd?
The Dividend Yield of Emmessar Biotech & Nutrition Ltd is 0.00 %.
What is the ROCE of Emmessar Biotech & Nutrition Ltd?
The ROCE of Emmessar Biotech & Nutrition Ltd is 12.6 %.
What is the ROE of Emmessar Biotech & Nutrition Ltd?
The ROE of Emmessar Biotech & Nutrition Ltd is 4.23 %.
What is the Face Value of Emmessar Biotech & Nutrition Ltd?
The Face Value of Emmessar Biotech & Nutrition Ltd is 10.0.